Máj- és epeúti rák: vizsgálatok itt: Németország
45 of 56 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 18.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043)
- Where
- Magdeburg
- Életkor
- 18 év and over
- People
- 134 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to join2025-524160-38-00 - 2. fázisTaking peopleVisugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
- Where
- Berlin, Cologne, Frankfurt Am Main, Freiburg im Breisgau, Hamburg, Hanover, Mainz, Ulm
- Életkor
- 18 év to 100 év
- People
- 104 worldwide
- Run by
- CatalYm GmbH
See details and how to joinNCT07219459 · EU 2025-520675-86-00 - No phaseTaking peopleTransarterial Chemoembolization (TACE) and Stereotactic Body Radiation (SBRT) in Patients With Hepatocellular Carcinoma (HCC) Prior to Liver Transplantation
- Where
- München
- Életkor
- 18 év and over
- People
- 44
- Run by
- AIO-Studien-gGmbH
See details and how to joinNCT07924943 - 1. fázisNot yet taking people in NémetországA Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Where
- Essen
- Életkor
- 18 év and over
- People
- 340 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07213791 · EU 2025-521887-37-00 - 2. fázisNot yet taking people in NémetországDB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- Where
- Frankfurt am Main, Giessen
- Életkor
- 18 év and over
- People
- 750 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00 - 1/2. fázisTaking peopleBOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours
- Where
- Bonn, Ulm
- Életkor
- 18 év and over
- People
- 220 worldwide
- Run by
- Bold Therapeutics, Inc.
See details and how to joinNCT04421820 · EU 2024-517500-11-00 - 3. fázisTaking peopleEfficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
- Where
- Berlin, Dresden, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Hanover, Heidelberg, Luebeck, Munich, Tuebingen
- Életkor
- 18 év and over
- People
- 286 worldwide
- Run by
- Jazz Pharmaceuticals
See details and how to joinNCT06282575 · EU 2023-508219-21-00 - 1/2. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Berlin, Dresden, Heidelberg, Heilbronn, Leipzig, Mainz, Muenster
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - 2. fázisTaking peopleDurvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extra- and Intrahepatic Cholangiocarcinoma
- Where
- Aachen, Bonn, Cologne, Duesseldorf, Frankfurt am Main, Goettingen, Hanover, Luebeck, Mainz, Muenster
- Életkor
- 18 év and over
- People
- 42
- Run by
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
See details and how to joinNCT06440993 · EU 2023-509165-21-00 - 1/2. fázisTaking peopleA Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
- Where
- Cologne, Frankfurt Am Main, Luebeck, Mainz
- Életkor
- 18 év and over
- People
- 198 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07291076 · EU 2025-523602-33-00 - 2. fázisNot yet taking people in NémetországEvaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
- Where
- Leipzig
- Életkor
- 18 év and over
- People
- 90 worldwide
- Run by
- Delcath Systems Inc.
See details and how to joinNCT06875128 · EU 2025-521966-91-00 - 1/2. fázisTaking peopleA Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
- Where
- Bochum, München, Ulm
- Életkor
- 18 év and over
- People
- 245 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07186842 · EU 2025-522613-26-00 - 3. fázisTaking peoplePhase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
- Where
- Berlin, Bonn, Cologne, Dresden, Frankfurt am Main, Freiburg im Breisgau, Goettingen, Hamburg, Leipzig, Luebeck, Munich, Ulm, Wuerzburg
- Életkor
- 18 év to 99 év
- People
- 620 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06467357 · EU 2023-508057-19-00 - 3. fázisTaking peoplePhase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- Where
- Aachen, Berlin, Bonn, Chemnitz, Cologne, Dortmund, Dresden, Erlangen, Essen, Frankfurt am Main, Frankfurt Am Main, Hamburg, Hanover, Leipzig, Luebeck, Magdeburg, Moers, Munich, Ulm
- Életkor
- 18 év and over
- People
- 1220 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06921785 · EU 2024-518210-81-00 - 1/2. fázisBefejeződöttSymbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
- Where
- Berlin, Bonn, Duesseldorf, Erlangen, Hanover, Mainz
- Életkor
- 18 év and over
- People
- 138 worldwide
- Run by
- Pfizer
See details and how to joinNCT07227012 · EU 2025-523525-17-00 - 1/2. fázisTaking peopleThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Where
- Augsburg, Essen, Frankfurt am Main, Hamburg, Heidelberg
- Életkor
- 12 év and over
- People
- 300 worldwide
- Run by
- PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750 - 1. fázisTaking peopleStudy of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Where
- Essen, Heidelberg, Herne, Jena, Nuertingen, Tuebingen
- Életkor
- 18 év and over
- People
- 1394 worldwide
- Run by
- Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00 - 1. fázisNot yet taking people in NémetországA phase I, open-label, dose-escalation, safety, pharmacokinetic/-dynamic and clinical activity study of p38α inhibitor Skepinone-L to enhance therapeutic efficacy of Sorafenib in advanced hepatocellular carcinomas of non-viral origin
- Where
- Tuebingen
- Életkor
- 18 év and over
- People
- 20
- Run by
- Universitaetsklinikum Tuebingen AöR
See details and how to join2024-511516-24-00 - 3. fázisTaking peopleA Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
- Where
- Aachen, Berlin, Bonn, Duesseldorf, Essen, Frankfurt am Main, Frankfurt Am Main, Freiburg im Breisgau, Hamburg, Heidelberg, Heilbronn, Karlsruhe, Magdeburg, Munich, Ulm
- Életkor
- 18 év and over
- People
- 1100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07221253 · EU 2025-523085-24-00 - 2. fázisVisszavonvaStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Where
- Berlin, Essen, Hanover, München, Regensburg
- Életkor
- 18 év to 130 év
- People
- 454 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00 - 1/2. fázisTaking peopleSafety of HRX215 in Patients After Minor and Major Liver Resection
- Where
- Essen, Tübingen
- Életkor
- 18 év to 75 év
- People
- 80 worldwide
- Run by
- HepaRegeniX GmbH
See details and how to joinNCT06638502 - 1. fázisTaking peoplePeptide Vaccine for Fibrolamellar Hepatocellular Carcinoma Patients and Other Tumor Entities Carrying the Driver Fusion DNAJB1-PRKACA
- Where
- Tübingen
- Életkor
- 12 év and over
- People
- 20
- Run by
- University Hospital Tuebingen
See details and how to joinNCT06789198 · EU 2024-519387-41-00 - No phaseNot yet taking people in NémetországLiver Transplantation for Non-Resectable Colorectal Liver Metastases Without Local Treatment Options
- Where
- Berlin
- Életkor
- 18 év to 65 év
- People
- 260
- Run by
- Charite University, Berlin, Germany
See details and how to joinNCT07811453 - No phaseTaking peopleEndoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma
- Where
- Berlin, Bonn, Chemnitz, Essen, Hamburg, Hanover, Heidelberg, Lübeck, Ulm
- Életkor
- 18 év and over
- People
- 130
- Run by
- Universitätsklinikum Hamburg-Eppendorf
See details and how to joinNCT06175845 - 3. fázisTaking peopleA Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR) altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308)
- Where
- Frankfurt am Main, Hamburg, Hanover, Heidelberg, Munich, Reutlingen
- Életkor
- 18 év and over
- People
- 126 worldwide
- Run by
- Transthera Sciences (Nanjing) Inc.
See details and how to join2023-505660-11-00